Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA4 | P22748 | 3/20 | 0.57 |
| ▸ | CA6 | P23280 | 3/20 | 0.57 |
| ▸ | CA5A | P35218 | 3/20 | 0.57 |
| ▸ | CA7 | P43166 | 3/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.57 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA3 | P07451 | 2/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.57 |
| ▸ | DPP4 | P27487 | 2/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | TYR | P14679 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3458431 | 1.00 | CA12 (0.57) | CA12CA1CA4CA6CA5A | |
| Biphenyl SCHEMBL28775810 | 0.92 | HDAC2 (0.56) | CA12CA1CA4CA6CA5A | |
| SCHEMBL27901081 | 0.89 | HCAR2 (0.53) | CA12CA1CA4CA6CA5A | |
| SCHEMBL10903830 | 0.87 | KDM4E (0.52) | CA12CA1CA4CA6CA5A | |
| SCHEMBL10903829 | 0.87 | KDM4E (0.52) | CA12CA1CA4CA6CA5A | |
| SCHEMBL17005583 | 0.86 | NPC1 (0.51) | CA12CA1CA4CA6CA5A | |
| SCHEMBL23854259 | 0.85 | HDAC3 (0.67) | CA12CA1CA4CA6CA5A | |
| SCHEMBL3225302 | 0.85 | HDAC3 (0.67) | CA12CA1CA4CA6CA5A | |
| SCHEMBL2300813 | 0.84 | HCAR2 (0.61) | CA12CA1CA4CA6CA5A | |
| SCHEMBL2300815 | 0.84 | HCAR2 (0.61) | CA12CA1CA4CA6CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| US-9273003-B2 | Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20140323531-A1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-10-30 | — | — | US | disclosed |
| US-8637547-B2 | Compounds which inhibit members of the histone deacetylase family of enzymes and their use in the treatment of cell proliferative diseases | CHROMA THERAPEUTICS LTD. (GB) | 2014-01-28 | — | — | US | disclosed |
| US-20130197042-A1 | HDAC INHIBITORS | CHROMA THERAPEUTCS, LTD | 2013-08-01 | — | — | US | disclosed |
| US-8350033-B2 | 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2013-01-08 | — | — | US | disclosed |
| EP-2213666-B1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | LI JIAMING (CN) | 2012-02-15 | — | — | EP | disclosed |
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2010-09-09 | — | — | US | disclosed |
| EP-2213666-A1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | Li, Jiaming (CN) | 2010-08-04 | — | — | EP | disclosed |
| US-20100010010-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2069291-A1 | HDAC INHIBITORS | Chroma Therapeutics Limited (GB) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008040934-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-04-10 | — | — | WO | disclosed |
| US-4053415-A | UNSATURATED POLYESTER ETHER HAVING A PHOTOCROSSLINKABLE MOIETY | FUJI PHOTO FILM CO., LTD. (JA) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323531-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | CA12 507/4885CA1 97/4885CA4 143/4885 |
| US-20100010010-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | CA12 494/4885CA1 97/4885CA4 141/4885 |
| US-20160137594-A1 | HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | CA12 1932/4885CA1 541/4885CA4 950/4885 |
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | AHR, CYP3A5, CYP3A43 | CA12 3619/4885CA1 4639/4885CA4 3912/4885 |
| US-20130197042-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | CA12 507/4885CA1 97/4885CA4 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.